INVESTORS
Investors Overview:
To date, Promentis has raised more than $31M total in equity financing, with the most recent Series C financing totaling $26 million.
INVESTORS
![image](https://promentispharma.com/wp-content/uploads/2017/03/image.png)
![image2](https://promentispharma.com/wp-content/uploads/2017/03/image2.png)
![aisling-capital](https://promentispharma.com/wp-content/uploads/2017/02/aisling-capital.png)
![Logo_Black_Pearl_Investments-300x118 Black_Pearl_Investments](https://promentispharma.com/wp-content/uploads/2017/02/Logo_Black_Pearl_Investments-300x118-300x118.png)
![image4](https://promentispharma.com/wp-content/uploads/2017/03/image4-300x118.png)
GRANT AWARDS
![US-NIH-NIMH-Logo National Institute of Mental Health](https://promentispharma.com/wp-content/uploads/2017/02/US-NIH-NIMH-Logo.jpg)
![image5](https://promentispharma.com/wp-content/uploads/2017/03/image5.png)
TECHNOLOGY
Novel oral compounds engaging SystemXC-, a CNS target for diverse psychiatric disorders
LEARN MORE